NCT04667299

Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment

Bismuth-Metronidazole Triple Versus Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Randomized Controlled Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 270 (estimated)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This randomized controlled clinical trial will compare the eradication efficacy of bismuth-metronidazole triple therapy (PPI+bismuth+ metronidazole) with that of bismuth-metronidazole quadruple therapy (PPI+bismuth+ metronidazole+ amoxicillin) for Helicobacter pylori first-line treatment. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	Rabeprazole	20mg bid
DRUG	Bismuth potassium citrate	0.6g bid
DRUG	Metronidazole	0.4g qid
DRUG	Amoxicillin	1g bid

Timeline

• Start date: 2020-12-20
• Primary completion: 2021-11-20
• Completion: 2021-12-31
• First posted: 2020-12-14
• Last updated: 2020-12-22

Locations

1 site across 1 country: China